# name
Factors associated with the clinical outcome of patients with relapsed/refractory CD19+acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

# metadata.dc.contributor.author[].value
Fernández de Larrea Rodríguez, Carlos José

# metadata.dc.description.abstract[].value
The prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hema-topoietic cell transplantation (alloHCT). Novel agents such as inotuzumab ozogamicin or blinatumomab achieve increased response rates, but these are generally transient unless followed by alloHCT. Chimeric antigen receptors (CAR) targeting CD19 have shown promising results in R/R ALL, and one of these products (tisagenlecleucel) has been approved for the treatment of patients with R/R ALL up to 25 years of age.

# metadata.dc.relation.ispartof[].value
Journal for ImmunoTherapy of Cancer , 2021, vol. 9, num. 12, p. e003644

# metadata.dc.rights[].value
cc-by-nc (c) Ortiz-Maldonado, Valentín et al., 2021

# metadata.dc.source[].value
Articles publicats en revistes (Medicina)

# metadata.dc.title[].value
Factors associated with the clinical outcome of patients with relapsed/refractory CD19+acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy